Skip to main content
. 2017 Feb 16;8(16):26169–26184. doi: 10.18632/oncotarget.15410

Figure 6. In vivo efficacy of 17-AAG on human GBC xenografts.

Figure 6

(A and B) Tumor growth of mice harboring G-415 tumors. G-415 cells were injected subcutaneously into NOD-SCID mice. When tumors reached a volume of approximately 50 mm3, they were treated with 17-AAG or vehicle, as described in the materials and methods section. Animals were sacrificed at day 34 after treatment initiation. Data are expressed as mean ± SD. 17-AAG exerted a statistically significant antitumor effect compared to the groups treated with vehicle (*P < 0.05 at day 34). (C) Western blot analysis of HSP90 and HSP90 clients proteins of tumor tissue from mice treated with vehicle or 17-AAG.